ZYNE
Income statement / Annual
Last year (2022), Zynerba Pharmaceuticals, Inc.'s total revenue was $0.00,
and the percentage change from the previous year is not available.
In 2022, Zynerba Pharmaceuticals, Inc.'s net income was -$34.82 M.
See Zynerba Pharmaceuticals, Inc.,s key income statements, including revenue, expenses, profit, and income.
| Period |
FY-2022
|
FY-2021
|
FY-2020
|
FY-2019
|
FY-2018
|
FY-2017
|
FY-2016
|
FY-2015
|
FY-2014
|
FY-2013
|
| Period Ended |
12/31/2022 |
12/31/2021 |
12/31/2020 |
12/31/2019 |
12/31/2018 |
12/31/2017 |
12/31/2016 |
12/31/2015 |
12/31/2014 |
12/31/2013 |
| Operating Revenue |
$0.00 |
$0.00 |
$0.00 |
$0.00 |
$86.00 K |
$7.25 K |
$7.25 K |
$278.90 K |
$810.01 K |
$943.90 K |
| Cost of Revenue |
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
| Gross Profit |
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$86.00 K
|
$7.25 K
|
$7.25 K
|
$278.90 K
|
$810.01 K
|
$943.90 K
|
| Gross Profit Ratio |
0
|
0
|
0
|
0
|
1
|
1
|
1
|
1
|
1
|
1
|
| Research and Development Expenses |
$21.10 M
|
$21.42 M
|
$35.65 M
|
$20.38 M
|
$27.25 M
|
$22.81 M
|
$16.78 M
|
$7.45 M
|
$2.40 M
|
$1.13 M
|
| General & Administrative Expenses |
$14.15 M
|
$15.35 M
|
$16.41 M
|
$13.94 M
|
$13.24 M
|
$10.02 M
|
$6.43 M
|
$5.36 M
|
$4.08 M
|
$444.30 K
|
| Selling & Marketing Expenses |
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
| Selling, General & Administrative Expenses |
$14.15 M
|
$15.35 M
|
$16.41 M
|
$13.94 M
|
$13.24 M
|
$10.02 M
|
$6.43 M
|
$5.36 M
|
$4.08 M
|
$444.30 K
|
| Other Expenses |
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
| Operating Expenses |
$35.25 M
|
$36.77 M
|
$52.06 M
|
$34.32 M
|
$40.48 M
|
$32.82 M
|
$23.21 M
|
$12.81 M
|
$6.48 M
|
$1.58 M
|
| Cost And Expenses |
$35.25 M
|
$36.77 M
|
$52.06 M
|
$34.32 M
|
$40.48 M
|
$32.82 M
|
$23.21 M
|
$12.81 M
|
$6.48 M
|
$1.58 M
|
| Interest Income |
$846.86 K
|
$21.05 K
|
$243.99 K
|
$1.52 M
|
$961.32 K
|
$519.55 K
|
$80.22 K
|
$0.00
|
$0.00
|
$0.00
|
| Interest Expense |
-$215.73 K
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
| Depreciation & Amortization |
$631.13 K
|
$559.68 K
|
-$481.72 K
|
$145.91 K
|
$99.57 K
|
$94.21 K
|
$75.30 K
|
$26.03 K
|
$27.06 K
|
$49.39 K
|
| EBITDA |
-$34.62 M |
-$36.21 M |
-$52.06 M |
-$34.17 M |
-$40.40 M |
-$32.82 M |
-$23.21 M |
-$12.51 M |
-$5.64 M |
-$585.05 K |
| EBITDA Ratio |
0
|
0
|
0
|
0
|
-469.74
|
-4527.31
|
-3201.05
|
-44.84
|
-6.96
|
-0.62
|
| Operating Income Ratio |
0
|
0
|
0
|
0
|
-469.74
|
-4527.31
|
-3201.05
|
-44.93
|
-7
|
-0.67
|
| Total Other Income/Expenses Net |
$215.73 K
|
-$538.63 K
|
$725.71 K
|
$1.38 M
|
$486.66 K
|
$810.71 K
|
-$208.42 K
|
$7.35 K
|
-$1.84 K
|
-$2.35 K
|
| Income Before Tax |
-$35.04 M
|
-$37.31 M
|
-$51.34 M
|
-$32.94 M
|
-$39.91 M
|
-$32.01 M
|
-$23.42 M
|
-$12.52 M
|
-$5.67 M
|
-$636.79 K
|
| Income Before Tax Ratio |
0
|
0
|
0
|
0
|
-464.08
|
-4415.49
|
-3229.8
|
-44.9
|
-7
|
-0.67
|
| Income Tax Expense |
-$215.73 K
|
$291.49 K
|
-$932.75 K
|
-$1.51 M
|
$0.00
|
-$27.54 K
|
-$27.54 K
|
$27.54 K
|
$0.00
|
$0.00
|
| Net Income |
-$34.82 M
|
-$37.60 M
|
-$50.40 M
|
-$31.43 M
|
-$39.91 M
|
-$32.01 M
|
-$23.39 M
|
-$12.55 M
|
-$5.67 M
|
-$636.79 K
|
| Net Income Ratio |
0
|
0
|
0
|
0
|
-464.08
|
-4415.49
|
-3226
|
-45
|
-7
|
-0.67
|
| EPS |
-0.82 |
-0.96 |
-1.87 |
-1.43 |
-2.61 |
-2.48 |
-2.58 |
-2.82 |
-0.99 |
-0.11 |
| EPS Diluted |
-0.82 |
-0.96 |
-1.87 |
-1.43 |
-2.61 |
-2.48 |
-2.58 |
-2.82 |
-0.99 |
-0.11 |
| Weighted Average Shares Out |
$42.66 M
|
$39.26 M
|
$27.02 M
|
$22.00 M
|
$15.31 M
|
$12.91 M
|
$9.07 M
|
$4.46 M
|
$5.73 M
|
$5.73 M
|
| Weighted Average Shares Out Diluted |
$42.66 M
|
$39.26 M
|
$27.02 M
|
$22.00 M
|
$15.31 M
|
$12.91 M
|
$9.07 M
|
$4.46 M
|
$5.73 M
|
$5.73 M
|
| Link |
|
|
|
|
|
|
|
|
|
|
